Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.
The neurological disorder destroys the myelin sheath protecting nerve fibers, caused by a mutation in the GFAP gene.
